OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
AFMDQ
Affimed N.V.
Common Stock
0.037
-0.007
-15.91%
0.037 / 0.042 (1 x 1)
Real-Time Best Bid & Ask: 05:00pm 07/11/2025
Delayed (15 Min) Trade Data: 12:00am 07/11/2025
Warning! Limited Information
The Pink Limited Market is for broker-dealers to publicly quote securities with limited to no issuer involvement. Pink Limited companies do not certify their compliance with established reporting standards, have limited availability of disclosure or financial information and may not support their U.S. market. These securities are identified with a yield sign to warn investors to proceed with caution.Warning! This company is in bankruptcy!
Click here to learn more about the bankruptcy reorganization process.0.044
0.037 - 0.044
19,570
N/A
Real-Time Level 2 Quote
Bid
Ask
MPID MPID | Bid Price Bid Price | Size Size | Time Time |
|---|---|---|---|
ETRF | 24.90 | >year | |
CDEL | 21.92 | 03/16 | |
MACM | 18.95 | >year | |
NITE | 18.95 | >year | |
CSTI | 18.55 | >year |
MPID MPID | Ask Price Ask Price | Size Size | Time Time |
|---|---|---|---|
INTL | 19.40 | >year | |
NITE | 19.40 | >year | |
MACM | 19.43 | >year | |
MAXM | 20.11 | >year | |
CANT | 22.05 | >year |
Unlock Real-Time quotes For AFMDQFind Out More
Trade Data
Date Date | Timestamp Timestamp | Price Price | $ Change $ Change | Volume Volume |
|---|---|---|---|---|
| 07/11/2025 | 14:17:35 | 0.037 | 0.00 | 237 |
| 07/11/2025 | 14:10:33 | 0.037 | -0.01 | 220 |
| 07/11/2025 | 13:59:30 | 0.042 | 0.01 | 440 |
| 07/11/2025 | 13:51:59 | 0.037 | -0.01 | 2,000 |
| 07/11/2025 | 13:38:07 | 0.042 | 0.00 | 345 |
News
Not available
Filings and Disclosure
Company Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.
Videos
This company has not added any videos
The Pink Limited Market is for broker-dealers to publicly quote securities with limited to no issuer involvement. Pink Limited companies do not certify their compliance with established reporting standards, have limited availability of disclosure or financial information and may not support their U.S. market. These securities are identified with a yield sign to warn investors to proceed with caution.
Pink Limited Information
This security has entered a 15 calendar day Grace Period because OTC Markets Group is unable to confirm that the issuer's disclosure is current and publicly available under Rule 15c2-11. It will be downgraded to the Expert Market at the end of this Grace Period unless OTC Markets Group determines another exception under Rule 15c2-11 applies, such as the Large Company/ADTV exception.
Company is not current in its reporting obligations under Section 13 or 15(d) of the Exchange Act.
This company is currently in Bankruptcy or reorganization proceedings.
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
57.41
Change
0.41 (0.72%)
Bid
57.40
Ask
58.40
Volume
667
Time
00:00
